Google and Singapore-based microbiome company AMILI launched AMILI Optimise at the end of April 2026, an app that asks users to submit fecal samples, wear a continuous glucose monitor and photograph every meal so that Google’s Gemini AI can turn that data into daily, individualized food recommendations. The partnership, first announced at the Google for Singapore event on February 10, 2026, is one of the most ambitious commercial tests yet of whether AI can translate the notoriously messy science of the gut microbiome into advice precise enough that people will pay for it — AMILI is charging SGD$750 (about US$584) for the program, discounted to SGD$400 (US$312) at launch.
How the Eight-Week Program Works
According to AMILI CEO and co-founder Dr. Jeremy Lim, the service unfolds in three phases over an initial eight-week window. Phase one combines a user’s gut microbiome profile with their postprandial blood glucose response — how blood sugar spikes after specific meals — to generate personalized nutrition recommendations. Phase two layers in restaurant and meal suggestions pulled through Google Maps integration, and phase three is meant to widen into an ecosystem involving governments, insurers and employers, positioning AMILI Optimise as more than a consumer wellness app. Users feed the system daily meal photos, continuous glucose monitor readings, fecal samples and self-reported questionnaires on mood and energy, which Google’s Gemini models process alongside AMILI’s Asian-centric gut microbiome database — a dataset the company says spans petabytes of microbiome, diet, sleep and stress information collected specifically from Asian populations, a group historically underrepresented in Western-centric microbiome research.
Part of a Much Bigger Money Flow
AMILI Optimise is landing in a gut-health market that investors have already poured roughly $500 million into over the past year, according to industry tracking cited in coverage of the sector. That capital has fueled products ranging from Throne, a toilet-attached device that analyzes bowel and urinary health, to Zoe’s at-home testing kits and Khosla Ventures-backed Viome’s personalized supplement recommendations. The clearest signal of investor appetite came when PepsiCo acquired prebiotic soda maker Poppi for $1.95 billion, after Poppi had raised only about $39 million in venture funding — a return that has convinced venture firms gut health is one of the few consumer health categories where AI-personalization claims can translate directly into acquisition-scale valuations.
The Bull Case: Data at a Scale Individual Doctors Never Had
Backers of AI-driven gut health tools argue that the sheer volume of longitudinal data these apps collect — daily meals, glucose curves, mood logs, repeated stool samples — gives AI models a chance to spot patterns no single clinician visit could ever surface. Viome CEO Naveen Jain has argued publicly that AI-generated advice pulled from a person’s own biological data is fundamentally different from the generic dietary guidance a dietitian gives an entire population, because it can adjust in near real time as a person’s gut microbiome and glucose responses shift. Google’s own pitch echoes that logic: pairing Gemini’s pattern-recognition with AMILI’s regionally specific microbiome database, executives argue, could finally make “personalized nutrition” more than a marketing phrase for millions of users in Asia whose gut biology has rarely been studied at this scale.
The Skeptics: A Science That Still Doesn’t Behave Linearly
Clinicians and even some founders in the space are considerably more cautious. Throne founder Scott Hickle has said plainly that “the gut microbiome doesn’t work” through simple linear relationships, meaning a given bacterial signature doesn’t reliably predict a given dietary fix. Max Brondfield, a gastroenterologist at UC San Francisco, says he regularly sees patients who tried algorithm-recommended probiotics that did nothing measurable, and advises “a lot of caution” before consumers act on tailored supplement suggestions. A 2025 Lancet consensus statement went further, warning that microbiome testing broadly lacks sufficient evidence to support routine clinical use — a direct challenge to apps charging hundreds of dollars for recommendations framed as personalized medicine rather than wellness entertainment.
A Parallel Trend: People Are Already Asking AI About Their Guts Anyway
Whatever the scientific verdict on apps like AMILI Optimise, consumers are increasingly turning to general AI chatbots for health questions with or without a dedicated app: more than 200 million health-related queries reportedly reach ChatGPT each week, with seven in ten of those questions arriving outside normal clinic hours, when a doctor typically isn’t reachable. That pattern suggests demand for AI-mediated nutrition and gut-health guidance is already there regardless of whether the underlying science has caught up, raising the stakes for whether products like AMILI Optimise can demonstrate real outcomes rather than just responsiveness.
What to Watch as Phase Two Rolls Out
AMILI’s third phase — bringing insurers, employers and government health programs into the ecosystem — is the point at which the Google-AMILI partnership will face its sharpest test, since institutional payers typically demand outcome data that goes well beyond user satisfaction surveys. Whether AMILI Optimise can produce evidence sturdy enough to survive scrutiny from bodies citing the Lancet’s skepticism, while still delivering the personalized, real-time feel that has made Viome and similar services popular with consumers, will likely determine if 2026 marks the year AI-driven gut health graduates from wellness trend to something insurers are willing to underwrite.
